Elliot Norry Sells $3.45K of Adaptimmune Therapeutics Plc (ADAP) — SEC Form 4, Jan 05, 2022
Open-Market Net Sale · SEC Form 4
−$3,451
Equity position changed by -38.0%
Equity Position
1.39K sh
2,237 → 1,388
Equity Change
-38.0%
shares held after vs before
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Elliot Norry CIK 0001798117 |
Officer
|
Elliot Norry at Adaptimmune Therapeutics Plc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Adaptimmune Therapeutics Plc
| 2025-02-20 | Award | — | View |
| 2025-01-17 | Sell | -$3,243 | View |
| 2025-01-15 | Sell | -$12,920 | View |
| 2024-01-17 | Sell | -$14,106 | View |
| 2024-01-17 | Award | — | View |
Non-Derivative Securities Transactions
Footnotes (3)
- F1
- Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. Show more
- F2
- The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. Show more
- F3
- The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 10,332 ADSs and RSU-style options and other options covering an aggregate of 2,382,344 ordinary shares of the Issuer. Show more
Related filings at Adaptimmune Therapeutics Plc
5%+ Holders · 13D/G
1 filer
Other insiders at Adaptimmune Therapeutics Plc
-
Gavin Wood -$950
-
William C Bertrand Jr -$2.09K
-
Ali Behbahani -$229K
-
Ecor1 Capital, LLC -$6.89M
GET /v1/forms/4/0001104659-22-001669
API docs
View Original SEC Filing